PharmaCom BioVet, Inc., a leader in specialized veterinary oncology, has announced that it is executing a joint venture agreement with a research development company with an intellectual property portfolio. The purpose of this joint venture agreement is to finalize the development of a compound which has the potential to become a viable treatment of specific cancers for companion animals within the veterinary marketplace.

The compound is in the family of Histone Deacetylase (HDAC) inhibitors, which binds directly to the catalytic site of the enzyme thereby potentially blocking the substrate access. This compound could have the ability to inhibit class I and class II HDACs and potentially arrest cellular growth in a wide variety of transformed cells.

The company will be initially focused on targeted research and developmental activities on a very specific canine tumour type commonly found in the canine population with a view to commercializing any potential positive results.